The Next-Generation Biomanufacturing Market Size is valued at 22.76 Billion in 2023 and is predicted to reach 48.27 Billion by the year 2031 at a 10.2% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- Supportive regulatory frameworks and guidelines from agencies like the FDA and EMA encourage the adoption of next-generation biomanufacturing technologies.
- The ability to adapt fastly to changing market demands and customize production processes for different biologics is a significant driving factor.
- Asia Pacific region dominated the market & accounted for a global revenue share in 2023.
Biomanufacturing is the production process of biomolecules by utilizing biological services to use in medical & industrial applications. Next-generation biomanufacturing products provide superior services in terms of quality and efficiency compared to first-generation biomanufacturing products.
Major driving factors of the next-generation biomanufacturing market are rising government funding for the development of modern bioprocessing technologies, rapid adoption of advanced technologies, increasing investments by pharma companies to develop & adopt next-generation biomanufacturing products, growing patient population, and increasing awareness among the people regarding the benefits of next-generation biomanufacturing. With the growing demand for drugs and therapies, many biopharmaceutical companies prefer adopting next-generation biomanufacturing services to balance the process design, performance, & efficiency with time and cost. This development is estimated to propel the market growth opportunities over the forecast years. However, complex manufacturing and development procedures and a lack of specialized expertise may hinder the market growth during the estimated timeframe.
Competitive Landscape
Some Major Key Players In The Next-Generation Biomanufacturing Market:
- Applikon Biotechnology BV (Netherlands),
- bbi-biotech GmbH (Germany),
- Danaher Corporation (US),
- Eppendorf AG (Germany), Esco Group of Companies (US),
- GEA Group Aktiengesellschaft (Germany),
- Meissner Filtration Products, Inc. (US),
- Merck KGaA (Germany),
- PBS Biotech, Inc. (US),
- Pierre Guérin (France),
- Sartorius AG (Germany),
- Shanghai Bailun Biotechnology Co. Ltd. (China),
- Solaris Biotechnology Srl. (Italy),
- Thermo Fisher Scientific Inc. (US),
- ZETA GmbH (Austria),
Market Segmentation
The next-generation biomanufacturing market is segmented into medical applications, products, workflow, end-users, and regions. The medical applications segment comprises monoclonal antibodies, hormones, vaccines, recombinant proteins, and other applications. Due to their increasing medical applications, the monoclonal antibodies segment will dominate this market during the forecast years. Based on the products, the market is divided into continuous upstream biomanufacturing products, single-use upstream biomanufacturing products, and downstream biomanufacturing products. The market is classified into upstream and downstream biomanufacturing based on workflow. By end-users, the market is segmented into biopharmaceutical companies, CMOs (contract manufacturing organizations)/CDMOs (contract development and manufacturing organization), and research institutions. Biopharmaceutical companies are estimated to hold a significant market share in the coming years owing to the growing prevalence of chronic diseases and the high demand for protein/drug production. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
North America led the market due to the robust presence of large biopharmaceutical businesses, the improved infrastructure in biological research, and the rising usage of innovative technologies. The Asia-Pacific market is expected to witness the fastest growth during the forecast period due to the rapid adoption of advanced technologies, rising patient pool, and the high prevalence of chronic diseases. Apart from this, Europe holds the second position in this market regarding revenue share.
Recent Developments:
- In March 2023, Sartorius and LFB BIOMANUFACTURING, collaborate on the creation and production of cell lines. LFB BIOMANUFACTURING is a division of LFB, a well-known European business that supplies medical practitioners with plasma-derived pharmaceutical products. It specializes in therapeutic protein biomanufacturing.
Next-Generation Biomanufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 22.76 Billion |
|
Revenue forecast in 2031 |
USD 48.27 Billion |
|
Growth rate CAGR |
CAGR of 10.2 % from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Medical Applications, Products, Workflow, End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Applikon Biotechnology BV (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (US), Eppendorf AG (Germany), Esco Group of Companies (US), GEA Group Aktiengesellschaft (Germany), Meissner Filtration Products, Inc. (US), Merck KGaA (Germany), PBS Biotech, Inc. (US), Pierre Guérin (France), Sartorius AG (Germany), Shanghai Bailun Biotechnology Co. Ltd. (China), Solaris Biotechnology Srl. (Italy), Thermo Fisher Scientific Inc. (US), ZETA GmbH (Austria), and other. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
